Literature DB >> 21876253

Episodic memory decline predicts cortical amyloid status in community-dwelling older adults.

David G Darby1, Amy Brodtmann, Robert H Pietrzak, Julia Fredrickson, Michael Woodward, Victor L Villemagne, Amy Fredrickson, Paul Maruff, Christopher Rowe.   

Abstract

Intra-individual decline in memory and cognition is characteristic of prodromal Alzheimer's disease (AD) and may allow detection of very early AD pathology. Episodic memory task scores on a brief computerized cognitive battery (CogState) were prospectively evaluated at baseline, and 3-, 6-, 9-, 12-, and 24-months post-baseline. Linear mixed models were conducted to compute age-adjusted slopes. Subjects with slopes declining ≥90th percentile ("memory decliners") and age- and gender-matched subjects without such decline ("non-decliners") were studied with clinical, neuropsychological, and neuroimaging evaluations. Of 195 who completed 24-month evaluation (age 51 to 80 years), 15 memory decliners (mean age 62.7 years, SD 7.6) were identified, and matched with 33 non-decliners (mean age 63.3 years, SD 8.2). Amyloid-PET imaging was qualitatively abnormal with excess cortical amyloid accumulation in 7 memory decliners (46.7%) and 4 (12.1%) non-decliners (odds ratio 6.34), and quantitatively abnormal with standardized uptake value ratios >1.4 in 5 memory decliners (33.3%) and 2 (6.1%) non-decliners (odds ratio 8.3). One of the memory decliners and none of the non-decliners fulfilled criteria for mild cognitive impairment, but the groups did not differ with respect to subjective memory impairment, neuropsychological evidence of episodic memory impairment, or MRI imaging abnormalities. Intra-individual decline in episodic memory can be detected using a brief computerized cognitive performance test optimized to detect change in community-dwelling non-demented older persons and appears predictive of the presence of cerebral amyloid in about half of these persons. This approach may help detect early prodromal AD pathology in wider-scale community screening programs.

Entities:  

Mesh:

Year:  2011        PMID: 21876253     DOI: 10.3233/JAD-2011-110818

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  16 in total

Review 1.  Testing the right target and right drug at the right stage.

Authors:  Reisa A Sperling; Clifford R Jack; Paul S Aisen
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

2.  Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.

Authors:  Annie M Racine; Lindsay R Clark; Sara E Berman; Rebecca L Koscik; Kimberly D Mueller; Derek Norton; Christopher R Nicholas; Kaj Blennow; Henrik Zetterberg; Bruno Jedynak; Murat Bilgel; Cynthia M Carlsson; Bradley T Christian; Sanjay Asthana; Sterling C Johnson
Journal:  J Alzheimers Dis       Date:  2016-10-18       Impact factor: 4.472

3.  β-Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [¹¹C]AZD2184.

Authors:  Patrik Mattsson; Anton Forsberg; Jonas Persson; Lars Nyberg; Lars-Göran Nilsson; Christer Halldin; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-27       Impact factor: 9.236

Review 4.  Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.

Authors:  Richard J Caselli; Eric M Reiman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 5.  Applications of technology in neuropsychological assessment.

Authors:  Carolyn M Parsey; Maureen Schmitter-Edgecombe
Journal:  Clin Neuropsychol       Date:  2013-09-16       Impact factor: 3.535

6.  Fibrillar amyloid correlates of preclinical cognitive decline.

Authors:  Cynthia M Stonnington; Kewei Chen; Wendy Lee; Dona E C Locke; Amylou C Dueck; Xiaofen Liu; Auttawut Roontiva; Adam S Fleisher; Richard J Caselli; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2013-04-11       Impact factor: 21.566

7.  Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment.

Authors:  Nikki H Stricker; Emily S Lundt; Sabrina M Albertson; Mary M Machulda; Shehroo B Pudumjee; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Michelle M Mielke
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 8.  Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review.

Authors:  Dorene M Rentz; Mario A Parra Rodriguez; Rebecca Amariglio; Yaakov Stern; Reisa Sperling; Steven Ferris
Journal:  Alzheimers Res Ther       Date:  2013-11-21       Impact factor: 6.982

9.  A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance.

Authors:  Shehroo B Pudumjee; Emily S Lundt; Sabrina M Albertson; Mary M Machulda; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Michelle M Mielke; Nikki H Stricker
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

10.  Prevention strategies for Alzheimer's disease.

Authors:  Serge Gauthier; Liyong Wu; Pedro Rosa-Neto; Jianping Jia
Journal:  Transl Neurodegener       Date:  2012-06-28       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.